Sirius Genomics Taps Golden Helix for GWAS Analysis, Companion Dx Co-development
October 19, 2010
Sirius Genomics Taps Golden Helix for GWAS Analysis, Companion Dx Co-development
Vancouver, Canada-based Sirius Genomics is using arrays to develop a test to identify individuals who respond to the hormone vasopressin and similar compounds for the treatment of septic shock.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- 'Soft' Q1 Pushes Affymetrix to Bet on Applied Markets, Acquisitions to Restore Growth
May 3, 2011 / BioArray News - Affy Posts 6 Percent Decrease in Q2 Sales as it Prepares to Launch Next-Gen Genotyping Offering
July 28, 2009 / BioArray News - GenomeWeb Feature: Will the Future of Genomics be Consumer Driven?
March 4, 2013 / GenomeWeb Daily News - Affy Files CytoScan with FDA, Plans 'Aggressive' Marketing Campaign to Grow Cyto Business
February 19, 2013 / BioArray News - After 'Pivotal' 2012, Affy Looks to CytoScan, Axiom Genotyping Products to Drive Future Growth
February 5, 2013 / BioArray News